Title |
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson’s disease
|
---|---|
Published in |
Journal of Neurology, September 2012
|
DOI | 10.1007/s00415-012-6669-1 |
Pubmed ID | |
Authors |
Ashok Sriram, Herbert E. Ward, Anhar Hassan, Sanjay Iyer, Kelly D. Foote, Ramon L. Rodriguez, Nikolaus R. McFarland, Michael S. Okun |
Abstract |
It has been previously well established that the use of dopaminergic agents in Parkinson's disease may contribute to behavioral disturbances such as dopamine dysregulation syndrome (DDS), impulse control disorders (ICD), and punding. ICD and punding have been most commonly addressed by reducing dose or by discontinuing the use of a dopamine agonist. Treatment of DDS has proven more challenging, and to date there has been no standard approach. In this paper, we review a series of four patients who met criteria for DDS, who were all refractory to medication adjustments. The DDS symptoms responded by the addition of valproic acid in all cases. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 1 | 33% |
United Kingdom | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 64 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 10 | 16% |
Other | 9 | 14% |
Student > Bachelor | 8 | 13% |
Student > Master | 8 | 13% |
Researcher | 6 | 9% |
Other | 9 | 14% |
Unknown | 14 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 34% |
Psychology | 6 | 9% |
Neuroscience | 5 | 8% |
Biochemistry, Genetics and Molecular Biology | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Other | 6 | 9% |
Unknown | 19 | 30% |